VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx (NYSE AMERICAN: VNRX) announced that on April 22, 2026 the NYSE American accepted its plan of compliance to regain listing standards. The company has until August 6, 2027 to restore required stockholders' equity thresholds and will undergo periodic reviews during the Plan Period.
The Acceptance Letter does not affect current listing or the company's SEC reporting obligations.
Volition (NYSE AMERICAN: VNRX) launched the rNuQ™ webshop on April 20, 2026, selling ready-to-use recombinant nucleosomes developed over the past 10 years.
Manufactured in an ISO 13485 facility, products ship at +4 °C in a glycerol-free buffer. The move expands Nu.Q® Discover commercialisation after 86% revenue growth in 2025 and ~100 clients worldwide.
VolitionRx (NYSE AMERICAN: VNRX) reported full fiscal year 2025 results and a business update on March 31, 2026. Key metrics: 2025 revenue $1.7M (+40% YoY), Q4 revenue growth +133% YoY, operating expenses down $4.8M (17%), net loss down 14%, and net cash used in operations $19.7M (down 24%).
Post-year-end financings included $5.4M ATM proceeds, a $1.9M convertible note and warrant, and $1M non-dilutive regional funding with ~$0.9M conditional tranches expected.
Volition (NYSE AMERICAN: VNRX) secured €2.0 million (approximately $2.3 million) of non-dilutive financing from Namur Invest and Wallonie Entreprendre on March 31, 2026.
Proceeds will fund the Nu.Q® portfolio: the regulatory transition of Nu.Q® NETs (IVDD to IVDR), continued R&D on a Lateral Flow product to enable access in Low Income Countries, manufacturing expansion and anchoring operations in Wallonia. Total non-dilutive funding to-date exceeds $25 million.
Volition (NYSE AMERICAN: VNRX) announced a peer‑reviewed Mayo Clinic study showing elevated Nu.Q® H3.1 and H3R8 Citrulline nucleosome concentrations in trauma patients, with higher levels in those who developed venous thromboembolism (VTE).
The prospective study analyzed 674 trauma patients, suggesting Nu.Q® NETs could aid early risk identification and targeted prevention in trauma care.
Volition (NYSE AMERICAN: VNRX) presented an ELCC 2026 abstract showing that preoperative H3K27Me3-nucleosome levels measured by Nu.Q Cancer assays stratify non-small cell lung cancer prognosis.
High H3K27Me3 levels predicted poorer recurrence-free and overall survival; low levels indicated better outcomes and potential micro-metastatic detection, with poster data and prior studies cited.
VolitionRx (NYSE AMERICAN: VNRX) will host a conference call on Wednesday, April 1, 2026 at 8:30 a.m. U.S. Eastern Time to discuss full fiscal year 2025 financial results and provide a business update.
The live audio webcast will be available online, with telephone dial-ins for U.S./Canada, U.K., and international participants and a replay accessible until April 15, 2026 (Conference ID 13759627).
Senior management and scientific officers will present and take questions about 2025 events, subsequent developments, and upcoming milestones.
Volition (NYSE AMERICAN: VNRX) reported blinded validation results from 81 subjects showing strong detection performance using its Capture-Seq™ liquid biopsy for colorectal and lung cancer.
The cohort achieved ~95% detection for stage I and II cancers (I: 94% [17/18]; II: 96% [26/27]), overall sensitivity 93% (55/59) and specificity 95% (21/22). The company cites a combined $36 billion TAM ($23B MCED; $13B MRD) and says it is in active discussions with potential licensing partners to commercialize the technology.
Volition (NYSE AMERICAN: VNRX) reports a claimed world‑first method, Capture‑Seq™, producing >99% pure circulating tumor DNA (ctDNA) from plasma. The company submitted an updated manuscript and reports blinded cohort detection of 49/49 and 13/14 cancers. Volition cites a combined TAM of approximately $36 billion.
The company says it is in active discussions with diagnostic partners and expects the updated preprint on Research Square shortly.
Volition (NYSE AMERICAN: VNRX) completed validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan, enabling full automation in central laboratories.
The supply agreement allows Fujifilm Vet Systems to sell and perform the automated test across its Japanese central reference lab network; over 1,700 veterinary hospitals are registered and Japan has about 7 million pet dogs, indicating a sizeable addressable market.